Lebensbeschreibung des Schweizerischen Reformators Ulrich Zwingli : mit acht Kupferblättern und einer Nachahmung seiner handschrift.

Mode of access: Internet.

Anna Reinhard, Gattinn und Wittwe von, Ulrich Zwingli, Reformator : denk/Stück allernächst für Zürichs christliche Frauen, Töchter und ihre Freundinnen zus Archiven und Familienschriften bearbeitet, zu bezug auf das Säcular-Jahr MDCCCXIX mit dem Bildnisse von Regula Zwingli /

Includes bibliographical references.

Ursprung, Gang und Folgen der durch Ulrich Zwingli in Zürich bewirkten Glaubens-Verbesserung und Kirchen-Reform : Beytrag zur dritten Zürcher Sekular-Feyer im Jahr 1819.

Includes bibliographical references.

Ulrich Zwingli. Ein und zwanzig Gesänge.

Mode of access: Internet.

Ulrich Zwingli et son 'epoque /

"Indication des sources historiques où l'auteur a puisé pour composer cet ouvrage" : p. 519-521.

A memorial service for the four hundredth anniversary of the birth of the Swiss reformer, Ulric Zwingli.

Mode of access: Internet.

Huldrych Zwingli : dramatisches Bild aus der Pestzeit in Zürich in drei Akten /

Imprint date from preface.

Huldreich Zwingli : Geschichte seiner Bildung zum Reformator des Vaterlandes /

Mode of access: Internet.

Von freiheit der Speisen : Eine Reformationsschrift von Huldrich Zwingli, 1522 /

Mode of access: Internet.

Huldreich Zwingli und sein Reformationswerk zum vierhundertjährigen Geburtstage Zwinglis /

Mode of access: Internet.

Der politische Kampf um die religiöse Einheit der Eidgenossenschaft 1520-27 : Ein Beitrag zu Zwinglis Staatspolitik /

Vita: p. [iii].

Dr. Martin Luthers Leben /

Part 2 has separate title: Das Leben von Huldreich Zwingli und Johann Calvin.

Beiträge zur Kirchenverfassungsgeschichte und Kirchenpolitik,

Mode of access: Internet.

Ulrich Zwingli : zum Gedächtnis der Zürcher Reformation 1519 - 1919 /

Mode of access: Internet.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX) : an open-label randomised phase III trial

Background: Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer. Methods: In a multinational, multicentre, open-label, phase III trial, chemotherapy-naive patients (≥18 years) with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer were randomly assigned in a 1:1 ratio to chemotherapy plus cetuximab or just chemotherapy. Chemotherapy was cisplatin 80 mg/m 2 intravenous infusion on day 1, and vinorelbine 25 mg/m 2 intravenous infusion on days 1 and 8 of every 3-week cycle) for up to six cycles. Cetuximab-at a starting dose of 400 mg/m 2 intravenous infusion over 2 h on day 1, and from day 8 onwards at 250 mg/m 2 over 1 h per week-was continued after the end of chemotherapy until disease progression or unacceptable toxicity had occurred. The primary endpoint was overall survival. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00148798. Findings: Between October, 2004, and January, 2006, 1125 patients were randomly assigned to chemotherapy plus cetuximab (n=557) or chemotherapy alone (n=568). Patients given chemotherapy plus cetuximab survived longer than those in the chemotherapy-alone group (median 11·3 months vs 10·1 months; hazard ratio for death 0·871 [95% CI 0·762-0·996]; p=0·044). The main cetuximab-related adverse event was acne-like rash (57 [10%] of 548, grade 3). Interpretation: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer. Funding: Merck KGaA. © 2009 Elsevier Ltd. All rights reserved.